{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:892",
      "entity_text" : "MI",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pfam:PF00071",
      "entity_text" : "RAs",
      "entity_type" : "family"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Empagliflozin profoundly reduced CV mortality, whereas pioglitazone and GLP-1 RAs primarily reduced the risk of nonfatal MI and nonfatal stroke, so addition of empagliflozin to pioglitazone or a GLP-1 RA may produce a robust reduction in all three MACE components.",
  "reading_complete" : "2020-07-28T13:15:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:12:11Z",
  "trigger" : "reduced",
  "evidence" : [ "RAs primarily reduced the risk of nonfatal MI" ],
  "pmc_id" : "5481984",
  "score" : 0
}